|
Jardiance Met is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate.
Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. However, the effectiveness of Jardiance Met on reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease has not been established.
Limitations of Use -
It is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
|
